Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Subscribe To Our Newsletter & Stay Updated
